1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,240 | 5,360 | 20:58 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| Mo | Devyser Diagnostics AB: Devyser appoints Torben Thölix as the new Chief Commercial Officer | 310 | GlobeNewswire (Europe) | Devyser today announces the appointment of Torben Thölix as Chief Commercial Officer (CCO). Torben will lead Devyser's global commercial organization and join the executive management team, reporting... ► Artikel lesen | |
| 06.08. | Devyser Diagnostics AB: Devyser signs first commercial reagent rental agreement under Illumina collaboration in Italy | 354 | GlobeNewswire (Europe) | Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial agreement under its Systems Integrator collaboration with Illumina. The agreement, signed with an Italian... ► Artikel lesen | |
| 20.07. | Devyser Q2 2026 slides: revenue dips on distributor issues, profit holds | 1 | Investing.com | ||
| 20.07. | Devyser: Umsatz im zweiten Quartal sinkt um 10,7 % wegen Lageranpassung bei Vertriebspartner | 1 | Investing.com Deutsch | ||
| 20.07. | Devyser Diagnostics Announces Increase In Q2 Bottom Line | 1 | RTTNews | ||
| 20.07. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2026 | 571 | GlobeNewswire (Europe) | "As previously announced, the second quarter was weaker than expected. Sales were negatively impacted by a temporary inventory adjustment by our single largest distributor. Underlying demand remains... ► Artikel lesen | |
| 02.07. | Devyser Diagnostics AB: Sales in the second quarter of 2026 weaker than expected | 178 | GlobeNewswire (Europe) | Devyser Diagnostics AB (publ) (the "Company" or the "Group") announces that its preliminary sales for the second quarter of 2026 are weaker than indicated by the information and conditions available... ► Artikel lesen | |
| 25.06. | Devyser Diagnostics AB: Devyser secures SEK 8.9M five-year tender and strengthens Italian position | 403 | GlobeNewswire (Europe) | Devyser, a leading provider of advanced genetic testing solutions, has been awarded a tender in Regione Basilicata, Italy, with a total value of SEK 8.9 million. The tender includes several of Devyser's... ► Artikel lesen | |
| 22.05. | Devyser Diagnostics AB: Devyser strengthens its executive management team - Niklas Axelsson appointed new CFO and Sabina Berlin transitions to a new role within the company | 212 | GlobeNewswire (Europe) | Devyser today announces that Sabina Berlin, current CFO, will transition to a new role with responsibility for Investor Relations and Corporate Compliance. At the same time, the company has appointed... ► Artikel lesen | |
| 06.05. | Devyser Diagnostics AB: Bulletin from the Annual General Meeting of Devyser Diagnostics AB (publ) held on 6 May 2026 | 229 | GlobeNewswire (Europe) | The Annual General Meeting of Devyser Diagnostics AB (publ) ("Devyser" or the "Company") was held on Wednesday, 6 May 2026 at Bränningevägen 12, 120 54 Årsta. The main resolutions passed at the Meeting... ► Artikel lesen | |
| 27.04. | Devyser Diagnostics mit starkem Umsatzwachstum und positivem EBIT im ersten Quartal | - | Investing.com Deutsch | ||
| 27.04. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2026 | 823 | GlobeNewswire (Europe) | "Devyser is reporting its fourth consecutive quarter with a positive operating result. This is an outcome we are delivering in an external environment that continues to present challenges: headwinds... ► Artikel lesen | |
| 07.04. | Devyser Diagnostics AB: Devyser announces that Chief Commercial Officer will leave the company | 239 | GlobeNewswire (Europe) | Devyser Diagnostics AB today announces that the company's Chief Commercial Officer (CCO), Theis Kipling, has decided to leave Devyser to take up a position with another company.
"During Theis' time... ► Artikel lesen | |
| 01.04. | Devyser Diagnostics AB: Devyser completes acquisition of CyberGene AB and carries out issue of compensation shares | 442 | GlobeNewswire (Europe) | Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, announces that the acquisition of all shares in CyberGene AB ("CyberGene") that was announced on 11 February 2026 has today been... ► Artikel lesen | |
| 04.03. | Devyser Diagnostics AB: Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing | 472 | GlobeNewswire (Europe) | Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing (NGS) assay for genetic analysis of thalassemia and sickle cell disease (SCD) available on the European... ► Artikel lesen | |
| 12.02. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2025 | 522 | GlobeNewswire (Europe) | "The fourth quarter confirmed the positive earnings trend that we have seen throughout the year. Operating profit amounted to SEK 18.0 million (-3.7) for the quarter and to SEK 10.1 million (-62.3)... ► Artikel lesen | |
| 11.02. | Devyser Diagnostics AB: Devyser acquires Swedish company Cybergene AB and strengthens its position in the aneuploidy market | 943 | GlobeNewswire (Europe) | Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has entered into an agreement relating to the acquisition of 100 percent of the shares in Cybergene AB... ► Artikel lesen | |
| 28.01. | Devyser Diagnostics AB: Devyser enters Strategic Supply Agreement with Illumina to offer sequencing instruments and products | 744 | GlobeNewswire (Europe) | Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA sequencing and array-based technologies, to provide Illumina sequencing instruments and related products... ► Artikel lesen | |
| 08.12.25 | Devyser Diagnostics AB: Devyser secures a four-year tender in France for Devyser Compact | 287 | GlobeNewswire (Europe) | Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in Marseille, France, valued up to SEK 9.5 million over a 48-month period.
This tender with Assistance... ► Artikel lesen | |
| 04.12.25 | Devyser Diagnostics AB: Health Canada grants IVD approval to Devyser's NGS-based chimerism test, the first of its kind in Canada | 256 | GlobeNewswire (Europe) | Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been granted approval as Class III In Vitro Diagnostic (IVD) medical devices by Health Canada. With this we... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 80,46 | +1,28 % | Ihre wichtigsten Termine: Medtronic, Swiss Life, Gerresheimer & Paolo Alto Networks stehen heute im Fokus! | © Foto: picture alliance/ASSOCIATED PRESS/Gerresheimer AG - picture alliance/ASSOCIATED PRESS/Gerresheimer AGGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick... ► Artikel lesen | |
| HCA HEALTHCARE | 358,80 | +0,50 % | HCA Healthcare (HCA) Navigates Patient Volume Challenges While Reporting Growth | ||
| LANTHEUS | 87,10 | 0,00 % | Lantheus Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| CAREDX | 42,400 | 0,00 % | Canaccord initiates CareDx stock coverage with buy rating on testing | ||
| ENVISTA | 22,600 | +0,89 % | Envista sees dazzling future ahead in China | ||
| GT BIOPHARMA | 0,283 | -0,39 % | GT Biopharma, Inc.: GT Biopharma Reports Second Quarter 2026 Financial Results | Phase 1 trial evaluating GTB-3650 TriKE- remains ongoing, with an update anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE- in multiple solid tumor types known to express B7-H3... ► Artikel lesen | |
| SYNEOS HEALTH | - | - | Causaly and Syneos Health Partner to Raise the Scientific Intensity of Clinical Research | Collaboration embeds evidence-grounded agentic AI into scientific workflows across Syneos Health, accelerating research while strengthening scientific rigor, consistency, and sponsor valueLONDON... ► Artikel lesen | |
| CARMAT | 0,049 | 0,00 % | CARMAT SAS: EFICAS Study Results Confirm the Clinical Performance of the Aeson Total Artificial Heart as a Bridge-to-Transplant Therapy | The study's primary endpoint was achieved in 72.7% of the 55 patients implanted between December 2022 and May 2025.
This rate was significantly above the historical benchmark of 38% established... ► Artikel lesen | |
| CHEMOMETEC | 63,35 | +0,56 % | ChemoMetec A/S: ChemoMetec enters collaboration agreement with Roche Diagnostics | ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties' solutions in... ► Artikel lesen | |
| ARRAIL GROUP | 0,203 | -100,00 % | ARRAIL GROUP (06639): QUARTERLY UPDATE AND CONTINUED SUSPENSION OF TRADING | ||
| POLAREAN IMAGING | 0,002 | 0,00 % | Polarean: Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026 | ||
| PROMIMIC | 0,765 | -4,38 % | Promimic AB Q2 Sales Increase | ||
| FRESENIUS | 44,705 | -0,18 % | EQS-News: Schutzgemeinschaft der Kapitalanleger e.V.: Fresenius, Gerresheimer, TUI und viele weitere Unternehmen präsentieren sich im Rahmen der SdK-Anlegerforen | Emittent / Herausgeber: Schutzgemeinschaft der Kapitalanleger e.V.
/ Schlagwort(e): Konferenz/Konferenz
Fresenius, Gerresheimer, TUI und viele weitere Unternehmen präsentieren... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 39,460 | +0,41 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,360 | -0,46 % | AKTIEN IM FOKUS: Zinsanstieg birgt Gefahren für sichere Aktienhäfen | FRANKFURT (dpa-AFX) - Steigende Zinsen an den Kapitalmärkten haben zum Wochenbeginn die Aktienkurse von als sichere Anlagen geltenden Unternehmen belastet. Dazu zählen unter anderen die Immobilienwerte... ► Artikel lesen |
DEVYSER DIAGNOSTICS AB gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,070 (-1,33 %) liegt der Kurs bei 5,190 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVYSER DIAGNOSTICS AB finden Sie auf Wallstreet Online.